🇺🇸 Myelostim in United States
80 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 80
Most-reported reactions
- Vomiting — 12 reports (15%)
- Bone Pain — 10 reports (12.5%)
- Leukopenia — 10 reports (12.5%)
- Abdominal Pain — 9 reports (11.25%)
- Neutropenia — 8 reports (10%)
- Diarrhoea — 7 reports (8.75%)
- Pyrexia — 7 reports (8.75%)
- Anaemia — 6 reports (7.5%)
- Thrombocytopenia — 6 reports (7.5%)
- Mucosal Inflammation — 5 reports (6.25%)
Other Other approved in United States
Frequently asked questions
Is Myelostim approved in United States?
Myelostim does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Myelostim in United States?
IRCCS San Raffaele is the originator. The local marketing authorisation holder may differ — check the official source linked above.